Upstream Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum
Upstream Bio (Nasdaq: UPB), a clinical-stage biotechnology company focused on developing treatments for inflammatory diseases and severe respiratory disorders, has announced its participation in an upcoming investor event. CEO Rand Sutherland, MD will engage in a fireside chat at the Stifel 2025 Virtual Immunology and Inflammation Forum on September 15, 2025 at 10:30 a.m. ET.
The presentation will be accessible via live webcast in the Events section of the company's investor relations website, with a replay available after the event.
Upstream Bio (Nasdaq: UPB), una società biotecnologica in fase clinica focalizzata sullo sviluppo di terapie per malattie infiammatorie e gravi disturbi respiratori, ha annunciato la sua partecipazione a un prossimo evento per investitori. Il CEO Rand Sutherland, MD parteciperà a una conversazione informale (fireside chat) al Stifel 2025 Virtual Immunology and Inflammation Forum il 15 settembre 2025 alle 10:30 ET.
La presentazione sarà disponibile in webcast dal vivo nella sezione Eventi del sito per gli investitori della società, con una replica accessibile dopo l'evento.
Upstream Bio (Nasdaq: UPB), una compañía biotecnológica en fase clínica centrada en el desarrollo de tratamientos para enfermedades inflamatorias y trastornos respiratorios graves, ha anunciado su participación en un próximo evento para inversores. El CEO Rand Sutherland, MD participará en una charla informal (fireside chat) en el Stifel 2025 Virtual Immunology and Inflammation Forum el 15 de septiembre de 2025 a las 10:30 a.m. ET.
La presentación se podrá ver por webcast en directo en la sección Eventos del sitio web de relaciones con inversores de la compañía, y habrá una retransmisión disponible después del evento.
Upstream Bio (Nasdaq: UPB)는 염증성 질환 및 중증 호흡기 질환 치료제 개발에 주력하는 임상 단계 바이오테크 기업으로, 다가오는 투자자 행사에 참여한다고 발표했습니다. 최고경영자(CEO) Rand Sutherland, MD가 Stifel 2025 Virtual Immunology and Inflammation Forum에서 2025년 9월 15일 오전 10시 30분(동부시간)에 화기애애한 대화(fireside chat)에 참여합니다.
발표는 회사 투자자 관계 웹사이트의 이벤트 섹션을 통해 라이브 웹캐스트로 시청할 수 있으며, 행사가 끝난 후 재방송도 제공됩니다.
Upstream Bio (Nasdaq: UPB), une société de biotechnologie en phase clinique spécialisée dans le développement de traitements pour les maladies inflammatoires et les troubles respiratoires sévères, a annoncé sa participation à un prochain événement investisseur. Le PDG Rand Sutherland, MD prendra part à une discussion informelle (fireside chat) lors du Stifel 2025 Virtual Immunology and Inflammation Forum le 15 septembre 2025 à 10h30 ET.
La présentation sera accessible en webcast en direct dans la section Événements du site relations investisseurs de la société, avec une rediffusion disponible après l'événement.
Upstream Bio (Nasdaq: UPB), ein biotechnologisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von Therapien für entzündliche Erkrankungen und schwere Atemwegserkrankungen konzentriert, hat seine Teilnahme an einer bevorstehenden Investorenveranstaltung bekannt gegeben. CEO Rand Sutherland, MD wird an einem Fireside Chat beim Stifel 2025 Virtual Immunology and Inflammation Forum am 15. September 2025 um 10:30 Uhr ET teilnehmen.
Die Präsentation wird per Live-Webcast im Bereich "Events" auf der Investor-Relations-Website des Unternehmens zugänglich sein; eine Wiedergabe wird nach der Veranstaltung verfügbar sein.
- None.
- None.
WALTHAM, Mass., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, Chief Executive Officer of Upstream Bio, will participate in a fireside chat at the Stifel 2025 Virtual Immunology and Inflammation Forum on September 15, 2025 at 10:30 a.m. ET.
A live webcast of the fireside chat will be available under the Events tab on the Investors section of the Company’s website. A replay will be posted on the Company's website following the presentation.
About Upstream Bio
Upstream Bio is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. The Company is developing verekitug, the only known antagonist currently in clinical development that targets the receptor for thymic stromal lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. The Company has advanced this highly potent monoclonal antibody into separate Phase 2 trials for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP), severe asthma, and chronic obstructive pulmonary disease (COPD). Upstream Bio’s team is committed to maximizing verekitug’s unique attributes to address the substantial unmet needs for patients underserved by today’s standard of care. To learn more, please visit www.upstreambio.com.
Investor and Media Contact:
Meggan Buckwell
Director, Corporate Communications and Investor Relations
ir@upstreambio.com
FAQ
When is Upstream Bio (UPB) presenting at the Stifel 2025 Virtual Immunology Forum?
How can investors watch Upstream Bio's (UPB) Stifel presentation?
Who will represent Upstream Bio (UPB) at the Stifel 2025 Virtual Immunology Forum?
What is Upstream Bio's (UPB) main focus as a company?
